Large Cap Biopharmaceuticals Q1 2016 Metrics: Earnings Show Limited Growth Prospects

Two of our four top stocks large cap picks Abbvie and Bristol-Myers Squibb are up since we recommended them because of their growth potential in “Immuno-Oncology”.